Albert Benjamin 4

What Happened
Albert Benjamin, CEO and director of Health Catalyst (HCAT), received equity awards on Feb 25, 2026: 930,000 restricted stock units (RSUs) and 38,833 performance-based restricted stock units (PRSUs), for a total of 968,833 contingent units (reported at $0.00 per unit as awards). On Feb 26, 2026 he had 13,304 shares sold at $1.75 per share (total proceeds $23,253) to satisfy tax withholding associated with vesting.

Key Details

• Transactions: 2/25/2026 — Award/Grant (A) of 930,000 RSUs and 38,833 PRSUs (price reported $0.00); 2/26/2026 — Sale/Disposition (F) of 13,304 shares at $1.75 each, proceeds $23,253.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting/conditions: The RSUs vest 16.67% on March 1, 2026, then the remaining 83.33% in 10 equal quarterly installments (see footnote). The 38,833 PRSUs are performance-based and contingent on 2025 performance metrics.
• Tax withholding: The 13,304-share sale was a mandated "sell to cover" to satisfy tax withholding under the company's equity plan (non-discretionary), not a voluntary open-market sale by the CEO.
• Filing: Form filed Feb 27, 2026 and discloses transactions on Feb 25–26, 2026 (reported filing date available).

Context

• RSUs/PRSUs are awards that convert to shares if vesting and/or performance conditions are met; they are not cash purchases and do not imply a purchase-based bullish signal.
• The small sell (13,304 shares) was to cover taxes only, per company policy; such sell-to-cover transactions are routine following vesting.
• For retail investors, awards increase potential future share issuance; purchases by insiders are generally more indicative of conviction than awards or mandatory tax sales.